Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial.

@article{Caffo2008DocetaxelWO,
  title={Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial.},
  author={Orazio Caffo and Teodoro Sava and Evi Comploj and Annamaria Fariello and Fable Zustovich and Romana Segati and Cosimo Stanislao Sacco and Francesco Valduga and Gianluigi Cetto and Enzo Galligioni},
  journal={BJU international},
  year={2008},
  volume={102 9},
  pages={1080-5}
}
OBJECTIVE To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS Patients with progressive HRPC were randomized to receive docetaxel 70 mg/m(2) on day 1 (arm A), or docetaxel 70 mg/m(2) on day 2 plus oral EP three times daily, at a total daily dose of 840 mg, on days 1-5 (arm B). The primary objective of the trial was to evaluate the activity of the… CONTINUE READING

From This Paper

Topics from this paper.
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…